Kevin Sayer

Dexcom's continuous glucose monitoring (CGM) system consists of a small sensor inserted just under the skin that continuously measures interstitial glucose levels and wirelessly transmits readings to a smartphone app or receiver every five minutes — providing real-time blood sugar data, trend information, and customizable alerts for dangerous highs or lows. The Dexcom G7, the company's latest sensor, is roughly the size of a coin, lasts 10 days, requires no fingerstick calibration, and provides 60-second warm-up time. CGM has proven superior to traditional finger-prick blood glucose monitoring in clinical outcomes, reducing both HbA1c (the key measure of long-term blood sugar control) and time spent in dangerous hypoglycemia. Dexcom's historic market has been Type 1 diabetes (where patients produce no insulin and CGM is increasingly considered standard of care), but the far larger opportunity is Type 2 diabetes — a population of over 400 million globally, where CGM adoption is still in early stages. Dexcom's Stelo biosensor, a lower-cost, over-the-counter CGM for Type 2 and prediabetic users, represents this expansion. Key stock drivers include CGM adoption rates (particularly in Type 2 diabetes), sensor utilization and reorder rates, competitive dynamics against Abbott's FreeStyle Libre, insurance coverage expansion, international market penetration, and the impact of GLP-1 drugs on diabetes management paradigms.